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a b s t r a c t
The importance of peroxisomes in lipid metabolism is now well established and peroxisomes contain approximately 60 enzymes involved in these lipid metabolic pathways. Several acyl-CoA thioesterase enzymes
(ACOTs) have been identiﬁed in peroxisomes that catalyze the hydrolysis of acyl-CoAs (short-, medium-,
long- and very long-chain), bile acid-CoAs, and methyl branched-CoAs, to the free fatty acid and coenzyme
A. A number of acyltransferase enzymes, which are structurally and functionally related to ACOTs, have also
been identiﬁed in peroxisomes, which conjugate (or amidate) bile acid-CoAs and acyl-CoAs to amino acids,
resulting in the production of amidated bile acids and fatty acids. The function of ACOTs is to act as auxiliary
enzymes in the α- and β-oxidation of various lipids in peroxisomes. Human peroxisomes contain at least
two ACOTs (ACOT4 and ACOT8) whereas mouse peroxisomes contain six ACOTs (ACOT3, 4, 5, 6, 8 and 12).
Similarly, human peroxisomes contain one bile acid-CoA:amino acid N-acyltransferase (BAAT), whereas
mouse peroxisomes contain three acyltransferases (BAAT and acyl-CoA:amino acid N-acyltransferases 1 and
2: ACNAT1 and ACNAT2). This review will focus on the human and mouse peroxisomal ACOT and acyltransferase enzymes identiﬁed to date and discuss their cellular localizations, emerging structural information and
functions as auxiliary enzymes in peroxisomal metabolic pathways. This article is part of a Special Issue entitled: Metabolic Functions and Biogenesis of Peroxisomes in Health and Disease.
© 2012 Elsevier B.V. All rights reserved.

1. Introduction
Peroxisomes are nearly ubiquitous organelles present in yeast,
fungi, plants and animals and in the last number of years there has
been a huge increase in research into peroxisome biogenesis, peroxisomal lipid metabolism and the role of peroxisomes in human diseases.
The involvement of peroxins in peroxisome biogenesis disorders has
been widely studied, together with diseases associated with individual
enzyme deﬁciencies and has provided new insights into the functions

Abbreviations: ACNAT, acyl-CoA:amino acid N-acyltransferase; ACOT, acyl-CoA
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of peroxisomes in health and disease. There are numerous excellent reviews on peroxisome biogenesis disorders and peroxisomal fatty acid
oxidation defects ([1–3] and including two chapters in this current
Special Issue). Research including a combination of biochemical techniques, molecular biology and proteomics over the last number of
years, has been instrumental in the elucidation of the enzymatic pathways in peroxisomes for the β-oxidation and α-oxidation of acyl-CoAs,
glyoxylate metabolism, ether-phospholipid synthesis, cholesterol and
isoprenoid metabolism and bile-acid synthesis.
In recent years, a number of enzymes called acyl-CoA thioesterases
(ACOTs) and acyltransferases have been identiﬁed and characterized in
peroxisomes and distinct roles for these enzymes as auxiliary enzymes
in peroxisomal lipid metabolism have now been established. This review will focus on these ACOTs and acyltransferases identiﬁed to
date and their roles in peroxisomal lipid metabolism.
2. Identiﬁcation and characterization of acyl-CoA thioesterases
and acyltransferases in peroxisomes
In the 1950s, the ﬁrst identiﬁcation of acyl-CoA thioesterase
(ACOT) activity was published describing the partial puriﬁcation of
a succinyl-CoA thioesterase from pig heart [4]. In the intervening
years, advances in techniques led to the identiﬁcation and
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characterization of several different families of ACOTs as reviewed in
[5–8]. A nomenclature system was introduced in 2005, which is now
followed by the scientiﬁc community and new ACOT genes identiﬁed
are assigned the next available number [9]. Within the peroxisome,
several ACOTs have been identiﬁed and characterized that cleave
the thioester bond of acyl groups attached to coenzyme A (CoASH),
to release the free acid and CoASH (Fig. 1). The acyl groups have
been identiﬁed as long-, medium- and short-chain fatty acids, dicarboxylic acids, methyl-branched chain fatty acids and bile acids,
depending on the ACOT enzyme involved.
ACOTs are divided into two families, named the Type-I and Type-II
thioesterases, where the Type-I thioesterases, together with the acyltransferases, show a high degree of sequence similarity and structurally belong to the α/β-hydrolase superfamily, which is one of the largest
superfamilies of proteins. The Type-II thioesterases show a low degree
of sequence similarity to each other, however they are structurally related and were found to belong to the HotDog fold family of proteins
[10]. While the Type-I thioesterases are only found in (some) bacteria
and in the animal kingdom (not in yeast, insects or plants), the Type-II
thioesterases are found in all three branches of life. Numerous HotDog
domain-containing proteins are fusion proteins in which two separate
genes have been fused to give a protein with two functional domains
(as is the case for ACOT12 discussed below).
The second group of enzymes identiﬁed in peroxisomes is the acylCoA:amino acid N-acyltransferases, which catalyze the transfer of carboxylic acids from the CoA ester to an amino acid, usually taurine or glycine
(Fig. 1). The ﬁnal step in bile-acid synthesis is a conjugation (or amidation) of the bile acids, producing taurine or glycine conjugated bile acids
that are excreted into the bile. This reaction is catalyzed by the wellcharacterized bile acid-CoA:amino acid N-acyltransferase (BAAT). More
recently, two further genes have been identiﬁed in mouse that code for
proteins that are sequence-related to BAAT, called Acnat1 and Acnat2
(acyl-CoA:amino acid N-acyltransferase 1 and 2), which function in the
conjugation of fatty acids to taurine (and possibly other amino acids).
The structures and functions of peroxisomal acyl-CoA thioesterases and
acyltransferases are the focus of this review.

3. Type-I peroxisomal acyl-CoA thioesterases
In the late 1980s and early 1990s the biochemical analysis of highly puriﬁed peroxisomes revealed ACOT activity with a wide range of
acyl-CoAs, including long-, medium- and short-chain acyl-CoAs
(from C2–C20-CoA) [11,12] and the partial puriﬁcation of a peroxisomal ACOT identiﬁed a protein with long-chain acyl-CoA thioesterase activity [11]. Gene cloning subsequently identiﬁed several Acots
in mouse and human that contained peroxisomal type 1 targeting signals (PTS1) at their carboxyterminal end. These proteins comprise the
Type-I family of ACOTs, and mouse contains six closely related genes
(that show 66–93% sequence identity to each other), all localized in a
gene cluster on mouse chromosome 12 D3, and are named Acot1 to
Acot6 [13–16]. The human ACOT genes (4 genes in total) are all localized in a gene cluster on human chromosome 14q24.3 [17], named
ACOT1, ACOT2, ACOT4 and ACOT6.
In mouse the products of four of the six genes in the gene cluster
(ACOT3–6) are localized in peroxisomes, while mouse ACOT1 localizes
to cytosol and ACOT2 to mitochondria. ACOT3, ACOT4, ACOT5 and
ACOT6 are proteins of about 47 kDa that end with the amino acid sequences -AKL (ACOT3 and ACOT5), -CRL (ACOT4) and -SKL (ACOT6)
(see Table 1) and peroxisomal localization was conﬁrmed using green
ﬂuorescent fusion protein studies [14–16] and proteomic studies
(ACOT3, ACOT4 and ACOT6) in puriﬁed mouse kidney peroxisomes [18].
The two ﬁrst peroxisomal Type-I thioesterases characterized in
detail were the mouse ACOT3 and ACOT5. Expression of the recombinant proteins revealed that mouse ACOT3 is a long chain acyl-CoA
thioesterase (highest activity with C12–C18-CoA), whereas mouse
ACOT5 is a medium chain acyl-CoA thioesterase (highest activity
with C10-CoA). Interestingly, ACOT3 and ACOT5 had little or no activity toward 3-hydroxy-palmitoyl-CoA, an intermediate in peroxisomal
β-oxidation, suggesting that these enzymes hydrolyze the substrates/
products at the beginning and the end of individual β-oxidation cycles, but not the intermediates within the individual cycles [15]. Neither enzyme was active on CoA-esters of bile-acid intermediates
(choloyl-CoA or chenodeoxycholoyl-CoA), but both ACOT3 and

Fig. 1. Reactions catalyzed by peroxisomal acyl-CoA thioesterases and acyltransferases. The bile acid-CoA:amino acid N-acyltransferase (BAAT) catalyzes the conjugation (or amidation) of the CoA esters of bile acids to glycine or taurine, resulting in the production of glycine or taurine conjugated bile acids (the ﬁgure shows choloyl-CoA with glycine as the
acceptor, producing choloylglycine and coenzyme A (CoASH)). The acyl-CoA:amino acid N-acyltransferase 1 (ACNAT1) enzyme catalyzes the conjugation of fatty acids to taurine,
resulting in the production of N-acyl taurines and CoASH (the ﬁgure shows stearoyl-CoA (C18:0-CoA) and taurine, resulting in the production of N-stearoyl taurine). (BAAT can also
conjugate fatty acids to taurine and glycine in a similar reaction catalyzed by ACNAT1 but for simplicity only ACNAT1 is shown). Acyl-CoA thioesterases (ACOTs) catalyze the hydrolysis of acyl-CoA esters to produce the free fatty acid and CoASH (the ﬁgure shows stearoyl-CoA, resulting in the production of stearic acid and CoASH).
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ACOT5 were active on 4,8-dimethylnonanoyl-CoA (DMN-CoA, the
end product of β-oxidation of pristanic acid in peroxisomes), with
ACOT3 being more efﬁcient. Acot3 mRNA is expressed as two splice
variants, which show a tissue-speciﬁc expression in kidney and liver
[15]. In contrast, Acot5 is mainly expressed in white adipose tissue
and brain, followed by intestine, albeit at low levels [19]. However,
ACOT3 and ACOT5 are only present in rodents, as discussed below.
The mouse ACOT4 was identiﬁed as a 421 amino acid protein ending in -CRL [13,14], which was shown to be targeted to peroxisomes
when expressed in human skin ﬁbroblasts [14]. Kinetic characterization showed that the mouse ACOT4 was only active with succinylCoA (Vmax ≈ 4 μmol/min/mg protein, Km ≈ 13 μM) and glutaryl-CoA
(Vmax ≈ 1.1 μmol/min/mg protein, Km ≈ 37 μM) [14], which are dicarboxylic acids produced as a result of β-oxidation of even and odd
chain dicarboxylic acids, and glutaryl-CoA is also an intermediate in
lysine and tryptophan metabolism. Expression of mouse Acot4
mRNA was identiﬁed mainly in liver, kidney and proximal intestine,
with at least the former two organs being involved in dicarboxylic
acid formation and metabolism. As stated above, the human Type-I
ACOT gene cluster revealed only one functional peroxisomal gene,
ACOT4, which was a surprising ﬁnding, given that the mouse genome
contained four genes coding for peroxisomal Type-I ACOTs. The
human ACOT4 protein contains a variant PTS1 of -PKL, which efﬁciently targets the protein to peroxisomes [17]. However, functional
analysis revealed that the human ACOT4 protein in fact catalyzes
the hydrolysis of the same substrates as the combined activities of
mouse ACOT3, ACOT4 and ACOT5 (i.e. long-chain acyl-CoAs,
succinyl-CoA/glutaryl-CoA and medium-chain acyl-CoAs), and it was
proposed that convergent evolution of the human genome resulted
in an enzyme that apparently adopted the activities of three distinct
mouse enzymes [17]. The ACOT4 gene is found only in mammals
(from dolphin (Tursiops truncatus) to human) and the protein
seems to be peroxisomal in all species with -PKL being the most common PTS1, followed by -SKL, -CRL and -AKL. In human, analysis of the
genome also revealed the presence of a further gene on chromosome
19q13.12, which showed 91% sequence identity to the human ACOT4
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gene and contains a peroxisomal targeting signal of -PKL. However,
this gene on chromosome 19 lacks introns and contains several stop
codons, and is therefore apparently a non-functional pseudogene
[17].
As pointed out in a recent review [20], ACOT3 and ACOT5 are only
found in the mouse and the rat, suggesting that ACOT3 and ACOT5 are
products of gene duplications after the rat–mouse split and are therefore the result of a divergent evolution. Evolution of new activities is
often driven by a despecialization step followed by gene duplications
and subsequent specialization of the new activities [21,22]. It therefore appears that ACOT4 represents an ancestor protein with ‘promiscuous activity’ that after gene duplications results in enzymes with
higher speciﬁcity. Thus, the advantage of the promiscuous activity
of human ACOT4 to catalyze the hydrolysis of a wider range of substrates may be at the cost of catalytic efﬁciency since the separate
mouse ACOTs appear to be more efﬁcient with higher Vmax (with
≈7–20-fold higher speciﬁc activity in the mouse proteins compared
to the activity with the corresponding substrates by human ACOT4)
and similar or lower Km's [14,15,17].
This raises the question as to whether the apparent lack of longchain acyl-CoA thioesterase activity in humans catalyzed by Type-I
ACOTs is compensated for by other thioesterase enzymes. Notably,
human ACOT1 (which has been identiﬁed as a cytosolic enzyme)
and ACOT2 (identiﬁed as a mitochondrial enzyme) [17] contain a
variant PTS1 (-SKV), which may function as a ‘weak’ peroxisomal targeting signal resulting in dual peroxisomal/cytosolic localization [23]
or peroxisomal/mitochondrial localization. ACOT1 and ACOT2 catalyze the hydrolysis of acyl-CoAs of chain length C12–C20 saturated
acyl-CoAs, together with C16:1 and C18:1 with Km values between 2
and 5 μM and Vmax values ranging from 250 to 700 nmol/min/mg
[17]. Therefore it is possible that both ACOT1 and ACOT2 may be partially peroxisomal and thus contribute long-chain acyl-CoA thioesterase activity in human peroxisomes.
The ﬁnal peroxisomal enzyme encoded for by the Type-I gene
cluster in mouse was recently identiﬁed as Acot6 [16]. ACOT6 is a
419 amino acid polypeptide that is targeted to peroxisomes by a

Table 1
Characteristics of mouse peroxisomal acyl-CoA thioesterases and acyltransferases.
Gene

Other aliases

Chromosome, accession number
and protein family

C-terminal signal and conﬁrmed
peroxisomal localization [reference]

Acyl-CoA substrates

Acot3

PTE-Ia

-AKL [15,18]

Long-chain acyl-CoAs [15]

Acot4

PTE-Ib, Pte2b

-CRL [14,18]

Succinyl-CoA, glutaryl-CoA [14]

Acot5

PTE-Ic

-AKL [15]

Medium-chain acyl-CoAs [15]

Acot6

PTE-Id

-SKL [16,18]

Phytanoyl-CoA, pristanoyl-CoA [16]

Acot8

PTE-2, PTE1

-SKL [18,29]

Long-, medium- and short-chain acyl-CoAs,
bile acid-CoAs, branched chain acyl-CoAs [29,30].

Acot12

CACH-I, MGC105114,
mCACH-1, CACH

-SVL [18]

Short-chain acyl-CoAs (in rat) [49]

Baat

BACAT, BAT

12 D3
NP_599007
α/β hydrolase
12 D3
NP_599008
α/β hydrolase
12 D3
NP_663419
α/β hydrolase
12 D3
NP_766168
α/β hydrolase
2 H3
NP_573503
HotDog fold protein family
13 C3
NP_083066
HotDog fold protein family
4 B3
NP_031545
α/β hydrolase
4 B3
ABE98441
α/β hydrolase
4 B3
EU564338
α/β hydrolase

-SQL [88]

Bile acid-CoAs [119], long-chain acyl-CoAsa

-SKL [93]

Long-chain and very long-chain acyl-CoAs [93]

-SKL (Fig. 6)

Unknown

Acnat1

Acnat2

a

Activity of the recombinantly expressed human BAAT enzyme.
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carboxyterminal PTS1 -SKL. Mouse ACOT6 is active on phytanoyl-CoA
and pristanoyl-CoA, suggesting a role in regulation of the metabolism
of methyl-branched fatty acids [16]. Phytol, which is an important
source of methyl branched fatty acids in mammals, enters the body
via the diet and is metabolized to phytanic acid and subsequently is
α-oxidized in peroxisomes to produce pristanoyl-CoA [24,25]. The
identiﬁcation of ACOT6 that hydrolyzes phytanoyl-CoA and pristanoylCoA to phytanic acid/pristanic acid and CoASH, raised questions as to
the physiological function of ACOT6 in peroxisomes. Acot6 mRNA in
mouse showed highest expression in white adipose tissue and kidney,
similar to the expression of acyl-CoA oxidase 3 (ACOX3), the suggested
rate-limiting enzyme in the β-oxidation of methyl branched fatty
acids (although ACOX2 may contribute signiﬁcantly in kidney and
particularly in liver). Although liver and kidney are involved in αoxidation and β-oxidation of methyl branched fatty acids [26,27]
the expression of ACOT6 and ACOX3 in white adipose tissue identiﬁed a possible pathway for metabolism of phytanic acid and pristanic
acid in peroxisomes in this tissue. The α-methyl group in pristanic
acid is present in two stereoisomers, 2R and 2S, however only the
2S isomer undergoes β-oxidation [28], and therefore racemization
of 2R pristanoyl-CoA to 2S pristanoyl-CoA is required before it can
undergo three cycles of β-oxidation in peroxisomes, resulting in
the production of DMN-CoA. DMN-CoA, in contrast to pristanoylCoA, is a substrate for ACOT8 [29,30] (as discussed below) or
ACOT5 [15], or alternatively DMN-CoA can be transferred to carnitine by the carnitine octanoyltransferase (CROT) for transport to
the mitochondria and further oxidation [31]. Expression of the 2methylacyl-CoA racemase (AMACR), which has a dual localization
in peroxisomes and mitochondria, is low in white adipose tissue
[16] and therefore the function of ACOT6 may be to hydrolyze excess

2R-pristanoyl-CoA to 2R-pristanic acid and CoASH. ACOT6 activity is
insensitive to CoASH, suggesting that ACOT6 regulates intraperoxisomal levels of phytanoyl-CoA and pristanoyl-CoA independent of
CoASH levels. The released pristanic acid may exit the peroxisome
to become esteriﬁed into triacylglycerols or alternatively transported from white adipose tissue to liver or kidney for further oxidation (for review see [8]). Interestingly, ACOT6 does not show any
preference for either the 2R or 2S isomer of pristanoyl-CoA, which
would allow for the hydrolysis of accumulating 2R-pristanoyl-CoA. It is
also possible that accumulated 2R-pristanic acid is reactivated via the peroxisomal very long chain acyl-CoA synthetase inside peroxisomes to
allow for β-oxidation [32], or to remove it from the β-oxidation pathway,
and the resultant 2R-pristanic acid can be esteriﬁed into triacylglycerols
or undergo β-oxidization in liver after racemization (for overview see
Fig. 2).
In human, there is an ortholog of the mouse Acot6 and searches in
databases show that an ACOT6 gene is apparently found in all mammals, but not in non-mammalian species. The human Acot6 is however transcribed from the second exon, and translated from an ATG at
the end of exon 2, therefore resulting in a 207 amino acid protein
that contains a variant of the PTS1, -SKI, at its C-terminal end [17].
It is not clear whether this shorter protein is active since it only contains 15 amino acids N-terminal of the so-called nucleophilic elbow
(located in exon 3 of ACOT proteins), which is a key structural component of the catalytic machinery in α/β-hydrolases, and therefore the
shorter protein lacks the N-terminal domain that may be involved
in the formation of the active site as discussed in Section 6.1.
Although the mRNA is expressed in humans [17], the protein has
not yet been detected in human peroxisomes. The carboxyterminal
tripeptide -SKI present in human ACOT6 does not target the protein

Fig. 2. Functions of acyl-CoA thioesterases in peroxisomes. Various acyl-CoA esters are transported into the peroxisome via ABCD transporters and undergo β-oxidation. The resultant
products (shown as ‘acyl-CoAs’) are then substrates for ACOTs. Phytanoyl-CoA and pristanoyl-CoA can be hydrolyzed by ACOT6 resulting in the production of phytanic acid or pristanic
acid, which can either be re-esteriﬁed to CoASH inside peroxisomes by very long chain acyl-CoA synthetase (VLCS), or are exported from peroxisomes and can be further esteriﬁed into
triacylglycerols or be transported from white adipose tissue to liver for further β-oxidation in mitochondria. Short chain acyl-CoAs such as acetyl-CoA and propionyl-CoA are produced in
peroxisomes by β-oxidation. Acetyl-CoA is released following each cycle of β-oxidation, whereas propionyl-CoA is produced by the β-oxidation of bile acid intermediates and methyl
branched fatty acids, and in every second β-oxidation cycle of pristanic acid. Acetyl-CoA and propionyl-CoA are both substrates for ACOT12 and ACOT8, which following hydrolysis by
ACOTs would be exported as acetate or propionate to cytosol or mitochondria. Long- and medium-chain acyl-CoAs produced by β-oxidation of very long-chain acyl-CoAs in peroxisomes
can be hydrolyzed by ACOT3, ACOT5 or ACOT8 to release CoASH. These non-esteriﬁed long- and medium-chain fatty acids can either be re-esteriﬁed to CoASH inside peroxisomes by very
long-chain acyl-CoA synthetase (VLCS) or exported from peroxisomes, and medium-chain fatty acids may be transported out of the peroxisome. Finally, ACOT4 and ACOT8 can hydrolyze
succinyl-CoA and glutaryl-CoA to produce succinate and glutarate, which can be transported to mitochondria. Similarly ACOT8 can hydrolyze medium chain dicarboxylic acids (such as
adipyl-CoA, suberyl-CoA, sebacyl-CoA and dodecanedioyl-CoA — MC-DCA) to free fatty acids, which can be exported from peroxisomes. ACOT8 is the only ACOT identiﬁed in peroxisomes
that is regulated by CoASH and therefore the activity of ACOT8 will depend on the intra-peroxisomal CoASH levels, which will change under different physiological conditions.
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to peroxisomes, but results in a cytosolic localization in human skin
ﬁbroblasts, when fused to green ﬂuorescent protein (GFP) [17]. However, -SKI is conserved in ACOT6 in more than half of the compared
mammalian ACOT6 genes (17/33 different mammalian genomes),
followed by -SKL/-SRL (8/33), -SKM (6/33) and -NKM (2/33). The
PTS1 variant -SKM was shown to function as a partial PTS1 signal,
resulting in dual peroxisomal/cytosolic localizations in human skin ﬁbroblasts [33], suggesting that ACOT6 would be at least partially localized to peroxisomes in several species. In spite of the apparent lack of
peroxisomal localization of human ACOT6 in transfection experiments, it is still possible that ACOT6, as well as other proteins carrying
the -SKI variant, may be at least partially peroxisomal. Other examples of functional non-consensus PTS1 are the bile-acid conjugating
enzyme BAAT (carrying -SQL in the C-terminal end), which in proteomic analysis is present in rat liver peroxisomes [34], and hydroxyacid oxidase 1 (HAO1), which also ends -SKI [35]. In spite of weak
interaction between -SKI-containing peptides and PEX5 [36], HAO1
efﬁciently localizes to peroxisomes in human skin ﬁbroblasts [35]
and is found in rat liver peroxisomes as analyzed by proteomic analysis [34]. Thus, in spite of the conﬂicting data regarding the functionality of -SKI as a PTS1, it cannot yet be excluded that human ACOT6
may be at least partially localized in peroxisomes. Whether the
short form of ACOT6 folds into an active enzyme in humans and the
effect on substrate speciﬁcity remains an open question as discussed
below.
4. Characterization of peroxisomal Type-II acyl-CoA thioesterases
Peroxisomes contain two Type-II acyl-CoA thioesterases, ACOT8
and ACOT12. ACOT8 (which has been characterized under various
aliases, see Tables 1 and 2) was originally identiﬁed in 1997 as a protein that binds to the HIV-1 Nef protein [37,38]. Cellular localization
experiments demonstrated that the identiﬁed Nef-binding protein
(ACOT8) is peroxisomal due to a C-terminal PTS1 (-SKL), and that
co-expression of the Nef-binding protein with Nef resulted in a colocalization in peroxisomes (as further discussed below). Based on
its homology to Escherichia coli thioesterase II (tesB) it was identiﬁed
as a novel mammalian acyl-CoA thioesterase with a broad acyl-CoA
chain-length speciﬁcity, which was further characterized in human
and yeast [39], mouse and rat [29,30]. ACOT8 is a highly conserved
protein that is expressed from bacteria to man, including yeast and
plants but apparently not in insects. The bacterial homolog TEII,
which shows about 40% sequence identity to human ACOT8, hydrolyzes medium- to long-chain acyl-CoAs [40].
The Arabidopsis thaliana genome contains two genes coding for
peroxisomal ACOT8-like thioesterases (with C-terminal PTS1 signals
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of -AKL and -SKL, respectively), which show about 68% sequence
identity to each other. One of these ACOTs was characterized in detail
and shown to hydrolyze C12–C20 saturated and unsaturated acylCoAs, but based on the expression pattern in plant tissues it was suggested that the function of this ACOT is probably not linked to fatty
acid oxidation in plants [41].
A more in-depth kinetic characterization of the mouse ACOT8
showed two interesting features, namely an unusually broad acyl-CoA
substrate speciﬁcity with ACOT8 being active on all tested acyl-CoAs
ranging from two to twenty carbon atoms, saturated as well as
unsaturated fatty acids, methyl-branched fatty acids and bile-acid intermediates, with the highest activity seen with the methyl-branched fatty
acids and bile-acid intermediates [29,30]. The second feature is a strong
inhibition of activity by CoASH [29], which is not seen with the Type-I
ACOTs. The sensitivity to CoASH and the very broad substrate speciﬁcity
suggests a role for this enzyme in regulation of intraperoxisomal acylCoA/CoASH levels (by sensing CoASH levels) in order to optimize the
ﬂux of fatty acids through the β-oxidation system (Fig. 2). In contrast
to the peroxisomal Type-I ACOTs, ACOT8 show a broad tissue expression in mouse and human [29,37], and expression is regulated by
ﬁbrates and fasting via the peroxisome proliferator-activated receptor
alpha (PPARα), suggesting a role for ACOT8 in regulation of fatty acid
oxidation [29]. The human ACOT8 gene is located on chromosome 20
(20q13.12), contains 6 exons and a putative peroxisome proliferator response element (PPRE) at −438 bp, suggesting that expression of the
human gene is also under control of PPARα [29]. However, experimental or clinical data are sparse to unambiguously clarify the importance of
this enzyme in lipid metabolism. So far there is no report on gene deletion or deﬁciency of ACOT8 in mice or humans that is linked to impaired
lipid metabolism. Also, the effect of deletion of the ACOT8 ortholog
(Pte1) in yeast is not clear since it may cause a partial (about 50%)
growth defect on oleate [39] and in another report, yeast cells grew on
oleate without any obvious phenotype [42]. However, over-expression
of human ACOT8 in human and murine cell lines as well as in transgenic
mice was associated with peroxisome proliferation and increased lipid
accumulation (determined as number of lipid droplets) [43]. The peroxisome proliferation was associated with increased amounts of catalase
protein and increased levels of acyl-CoA oxidase 1 (Acox1) mRNA. All
these effects required active ACOT8 protein and also that the protein
was correctly targeted to peroxisomes, as the effects were abolished in
cells transfected with ACOT8ΔSKL or an ACOT8 mutant with strongly reduced enzymatic activity. Interestingly, the over-expression was also associated with increased PPARγ expression, suggesting that very high
ACOT8 activity causes lipid accumulation and possibly a more adipogenic
phenotype. Taken together, these data indicate that products of ACOT8
activity mediate peroxisome proliferation, possibly via PPARα, and that

Table 2
Characteristics of human peroxisomal acyl-CoA thioesterases and acyltransferases.
Gene

Other aliases

Chromosome, accession number
and protein family

C-terminal signal and conﬁrmed
peroxisomal localization [reference]

Acyl-CoA substrates

ACOT4

PTE-Ib, PTe-2b, hPTE-I

-PKL [17]

Succinyl-CoA, glutaryl-CoA, long-chain
acyl-CoAs [17]

ACOT8

PTE-2, hTE, hACTEIII, PTE1

-SKL [39]

Medium- and long-chain acyl-CoAsa [39]

ACOT12

CACH-1, MGC105114, CACH

-SKFb

Short-chain acyl-CoAs [48]

BAAT

BACAT, BAT

14q24.3
NP_689544
α/β hydrolase
20q12–q13.1
NP_005460
HotDog fold protein family
5q14.1
NP_570123
HotDog fold protein family
9q22.3
NP_001692
α/β hydrolase

-SQL [88]

Bile acid-CoAs, long- and very long-chain
acyl-CoAs [89] (Fig. 5)

a
Only tested with medium and long-chain acyl-CoAs but given the broad substrate speciﬁcity of the mouse and rat ACOT8, it is likely that human ACOT8 can hydrolyze a broad
range of acyl-CoAs, including bile acid-CoAs, branched chain acyl-CoAs and short-, medium- and long-chain acyl-CoAs.
b
Not conﬁrmed as peroxisomal in human. Mouse ACOT12 contains a -KSVL at its carboxyterminal and has been identiﬁed in peroxisomes (see Table 1).
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strong over-expression of ACOT8 inhibits peroxisomal β-oxidation to
such an extent that lipids accumulate in droplets. In the future it would
be of interest to challenge ACOT8 over-expressing cells with various
fatty acids/lipids that are substrates for peroxisomal β-oxidation to explore the lipid speciﬁcity of the observed phenotypes and to delete the
gene in e.g. mouse, and study the possible phenotypes in various tissues
since the other peroxisomal ACOTs show highly tissue-speciﬁc expression patterns.
A somewhat unexpected possible function of ACOT8 (Pte1) in Saccharomyces cerevisiae is the apparent involvement in the efﬁcient metabolism of straight and methyl-branched short- to medium-chain
fatty acids [44]. This study showed that polyhydroxyalkanoate synthesis and cell growth was somewhat impaired in pte1Δ strain cultured in the presence of 10-cis-heptadecenoic acid, and severely
impaired when 8-methyl-nonanoic acid was added to the medium.
Translation of these ﬁndings to the mammalian ACOT8 may suggest
a role in regulation of methyl-branched acyl-CoA levels, in line with
the high activity of ACOT8 with methyl-branched fatty acids and
bile acid intermediates [29,30].
4.1. Possible functions for ACOT8 in interaction with other proteins
As discussed above, ACOT8 was originally identiﬁed in 1997 as a
protein that interacted with the HIV-1 Nef [37,38]. Nef is a 27-kDa myristoylated cytosolic protein that associates with the plasma membrane
and other intracellular vesicle surfaces and is important for high virus
load and disease progression. Nef has multiple functions as it downregulates CD4 (cluster of differentiation), which is one of the receptors
for HIV, and the cell surface expression of major histocompatibility
complex class I (MHC-I). Nef also alters the state of T-cell activation
and macrophage signal transduction pathways and impairs the formation of immunological synapses. The interaction with ACOT8 relocalizes Nef to peroxisomes and mediates CD4 down-regulation.
There was a strong correlation between the interaction with ACOT8
and the ability of Nef alleles to induce CD4 down-regulation [38], and
abolishment of the protein–protein interaction by point mutations in
the core region of Nef abrogates the ability of Nef to down-regulate
CD4. However, not all CD4 down-regulating Nef alleles interacted
with ACOT8, leaving the role of ACOT8 in HIV infection uncertain [45].
If Nef is targeted to peroxisomes via its interaction with ACOT8, it is unlikely that Nef will exit peroxisomes since it appears that ‘once a protein
is inside the peroxisome it remains there’ [46]. In a recent review (‘Viruses exploiting peroxisomes’), Lazarow proposes some possible mechanisms by which ACOT8 may participate in the down-regulation of CD4
[47]. While N-terminal myristoylation is irreversible, palmitoylation of
cysteine residues is reversible and can be deacylated by acyl protein
thioesterases. It is possible that Nef-ACOT8 oligomers formed when
Nef is expressed during viral infection may not be completely targeted
to peroxisomes, but have multiple cellular locations and alternatively
Nef may target ACOT8 to the plasma membrane. If ACOT8 can function
as a protein thioesterase (which has apparently not been tested yet),
ACOT8 may deacylate Lck (lymphocyte-speciﬁc protein tyrosine kinase
p56 lck), which contains an N-terminal myristoylation and is palmitoylated on two cysteines that is essential for its association with the plasma membrane. Lck binds to the cytoplasmic tail of CD4 and thereby
preventing CD4 internalization. Removal of Lck would thus promote endocytosis of CD4, which would be further accelerated by Nef, however,
the possible role of ACOT8 (or some other thioesterase) in CD4 downregulation needs to be further substantiated experimentally.
4.2. The ACOT12 is a peroxisomal Type-II thioesterase in mouse that
hydrolyzes short chain acyl-CoAs
ACOT12 was ﬁrst isolated from rat liver as an extra-mitochondrial,
predominantly cytosolic, cold labile acetyl-CoA thioesterase that is
active on short-chain acyl-CoAs [48]. The enzyme shows unusual

physicochemical properties as ATP and ADP affects oligomerization
(monomers/dimers/tetramers/hexamers) and activity (ATP-stimulated and ADP-inhibited) of this enzyme [49,50]. Further subcellular
fractionation experiments showed that the enzyme is partially localized to peroxisomes, at least in rat liver, and treatment with cloﬁbrate
increases the activity about 4-fold [51]. Further evidence for a peroxisomal localization was obtained in mouse kidney by proteomic characterization [18]. Molecular cloning of the mouse, rat and human
ACOT12 enzymes revealed a novel structure with no sequence similarity to the Type-I enzymes, but shows 46–50% sequence identity
to mitochondrial ACOT11 [52]. ACOT11 and ACOT12 consist of three
domains, two (duplicated) thioesterase domains, referred to as HotDog domains, and a C-terminal Steroidogenic acute regulatory related
lipid transfer (Start) domain. Structurally these proteins are referred
to as double HotDog fold proteins and the acyl-CoA thioesterases represent the largest subfamily within the HotDog superfamily [10]. In
spite of the very low sequence similarity of ACOT8 to ACOT11 and
ACOT12, ACOT8 is also a double HotDog fold protein, but lacking the
Start domain. Structural analysis of the Start domain of ACOT11
(STARD14) suggests that it likely binds fatty acids, compatible with
the function of ACOT11 in hydrolyzing medium- to long-chain acylCoAs [53]. Sequence analysis of the rat and mouse ACOT12 enzymes
reveals a variant C-terminal PTS1 signal of -KSVL that is likely responsible for the partial peroxisomal localization in these species. However,
the human ACOT12 protein ends -STF (as in all primates) and of all species compared it appears that ACOT12 is only localized to peroxisomes
in rat and mouse. Thus, ACOT8 seems to be the only short-chain acylCoA thioesterase activity in human peroxisomes, although the human
ACOT8 appears to have lower short-chain acyl-CoA thioesterase activity
compared to the mouse enzyme [29,39]. As ACOT12 is localized in peroxisomes in mouse and shows a different tissue expression pattern
compared to peroxisomal carnitine acetyltransferase (Crat), the latter
which results in the production of acetyl/propionylcarnitine esters
(C2/C3-carnitine esters), it was proposed that ACOT12 and CRAT provide
alternative/complementary systems for transport of short-chain products of β-oxidation out of peroxisomes [19] (Fig. 2). It is therefore likely
that transport of short-chain β-oxidation products is different in mouse
and human peroxisomes.
5. Role of acyl-CoA thioesterases and acyltransferases in
metabolite transport
Peroxisomes have important functions in the degradation of a broad
spectrum of fatty acids, in particular fatty acids that are poorly oxidized
by mitochondria. Medium-chain fatty acids may be transported across
the peroxisomal membrane as free acids and are activated to the corresponding CoA ester inside the peroxisome [54]. In contrast, long-chain
fatty acids are activated outside the peroxisome, followed by transport
of the CoA esters across the peroxisomal membrane via ABCD1 or
ABCD2 (for review, see [55]). The peroxisomal β-oxidation system
mainly produces chain-shortened acyl-CoAs and acetyl/propionyl-CoA,
which are then transported out of the peroxisome. It is hypothesized
that the combined activities of ACOT3, ACOT4, ACOT5, ACOT6 and
ACOT8 result in the hydrolysis of a wide range of fatty acyl-CoA esters,
allowing transport of shorter fatty acids out of the peroxisome, while
long-chain β-oxidation substrates/products hydrolyzed by ACOT5 or
ACOT8 may be re-activated inside peroxisomes by the very long chain
acyl-CoA synthetase oriented to the peroxisomal matrix [32] (as outlined in Fig. 2). While ACOT3–6 have specialized functions (acyl-CoA
speciﬁcities), ACOT8 is a highly promiscuous thioesterase that hydrolyzes ‘all’ acyl-CoAs. However, the activity of ACOT8 is under strong regulation by CoASH, suggesting a role in sensing CoASH levels. So how are
these metabolites transported out of the peroxisome? Peroxisomes
contain carnitine acetyl and carnitine octanoyltransferases (CRAT and
CROT) that can convert short- to medium-chain acyl-CoAs to the corresponding carnitine ester for transport to mitochondria [56]. Recent work
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has shown that the peroxisomal membrane is permeable to small solute
molecules while larger, bulky molecules require membrane transporters
([57,58], as reviewed in [59] and in this current Special Edition [60]),
which has implications for the transport of both substrates and metabolites ‘in-and-out’ of peroxisomes. The peroxisomal membrane contains
three ABCD transporters that mediate the uptake of various acyl-CoA esters (reviewed in [61]) and an ATP/ADP/AMP transporter [62]. It was recently shown that Pxmp2 forms a membrane channel that enables free
diffusion of small solutes (b300 Da), and partially restricted diffusion of
solutes of >300 Dab 500–600 Da [58]. This implies that many, if not
most, of the products of peroxisomal ACOTs, ACNAT1 and the nudix hydrolase enzymes (NUDT7 and NUDT19 acyl-CoA diphosphatase enzymes
regulating acyl-CoA/CoASH homeostasis in peroxisomes [63,64]) may be
‘freely’ transported out of peroxisomes via Pxmp2. For a detailed review
on this subject, see [60] in this Special Issue.
6. Relationship of the crystal structure of human ACOTs to
their functions
6.1. Crystallization of Type-I acyl-CoA thioesterases
Sequence analysis, secondary structure predictions and site-directed
mutagenesis experiments identiﬁed the Type-I ACOTs as members of
the α/β-hydrolase protein superfamily, members of which contain a lipase/esterase active site motif that is characterized by a conserved serine residue (acting as a nucleophile) located in a GlyXaaSerXaaGly motif
(GxSxG) [65]. In addition these α/β-hydrolases contain a conserved histidine residue and an aspartic/glutamic acid residue, which together
with the nucleophile constitute a catalytic triad in this protein family.
The ﬁrst crystal structure of a Type-I ACOT, human ACOT2 that was published in 2009 [66] revealed an N-terminal and a C-terminal domain.
The N-terminal domain contains a seven-stranded β-sandwich and
the C-terminal domain having the characteristic α/β-hydrolase fold
of this Type-I thioesterase family. The Type-I ACOTs are encoded
for by three exons [13] of which the ﬁrst exon contributes the Nterminal domain and the second and third exons the C-terminal domain. In spite of the fact that the function of the N-terminal domain
is unknown, the ﬁrst and the (short) second exons are highly conserved suggesting important functions for the N-terminal domain.
The X-ray crystallographic structure of human ACOT4 was determined
in 2009 by the Structural Genomics Consortium at Karolinska Institutet,
Stockholm, Sweden. While coordinates are available in the PDB (PDB
ID: 3K2I), the detailed analysis of this structure will be published elsewhere (Siponen et al., manuscript in preparation) and a preliminary analysis of this structure is described. The structure of human ACOT4 exhibits
the same two-domain organization as other Type-I ACOT family members
and the high degree of sequence conservation within this subfamily has
revealed a high degree of structural similarity within the Type-I ACOTs.
Resembling the cytosolic human ACOT1 (Siponen et al., unpublished results) and mitochondrial human ACOT2 [66], human ACOT4 is structured
into an N- and a C-terminal domain (Fig. 3). Similar to other family members, the N-terminal domain of human ACOT4 contains a seven-stranded
β-sandwich, with one sheet having three short anti-parallel β-strands
and the other sheet having four longer anti-parallel β-strands. This domain was previously reported in the crystallographic structure of
human ACOT2 as having limited structural similarity with other
proteins [66].
The C-terminal domain of human ACOT4 has a central, mostlyparallel (with the exception of one strand), eight-stranded β-sheet
that is surrounded by ﬁve α-helices. This domain also contains two
short, three-stranded β-sheets, the ﬁrst being an anti-parallel sheet
on the surface, and the second partially covering the active site pocket. This domain also contains several protruding loops, notably in the
vicinity of the active site pocket. The C-terminal domain also contains
the catalytic triad Ser232-His360-Asp326 (as highlighted in Fig. 3).
These triad residues are located near the C-terminal end of the
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parallel β-strands in the central β-sheet. While the catalytic triad is
contained within this domain, the active site is actually located in a
large pocket at the interface between the N- and C-terminal domains
and several long loops from both domains contribute to the formation
of this active site. Although still very little is known concerning the
molecular level details of substrate speciﬁcity, it is likely that one or
more of these loops is involved in substrate recognition and/or binding. The structural data does not yet however explain the ‘dual’ substrate speciﬁcity of human ACOT4 (i.e. the long chain acyl-CoA
activity, and the succinyl-CoA/glutaryl-CoA activity) [17].
The human ACOT4 protein forms a dimer and analysis of the dimeric interface present in the crystallographic structure of human
ACOT4 shows that the buried surface area is rather big, more than
1400 Å, which is within the sizes observed for physiological protein–protein interactions. Inspection of the interface revealed that
several amino acids speciﬁc to human ACOT4 participate in the dimerization, forming a hydrophobic pocket that is solvent exposed in
other Type-I family members. This pocket is made up of residues
Phe90, Phe286 and Pro371 in the human ACOT4. This multimerization has also been conﬁrmed in solution by analytical size exclusion
chromatography and appears to be speciﬁc to ACOT4 (Siponen and
Berglund, unpublished results).
Based on the structure of ACOT2 and ACOT4, human ACOT6 would
be missing the N-terminal domain as well as the ﬁrst 4 strands of the
C-terminal domain but it was suggested that the remaining Cterminal domain could still form a stable structure [66]. However, in
the absence of the N-terminal domain the active site would be
‘open’ and thus the substrate speciﬁcity may be quite different from
the full-length (mouse) ACOT6 [66]. It would be of interest to solve
this issue, however attempts to express human ACOT6 as a recombinant fusion protein have so far failed to produce soluble protein
(Hunt and Alexson, unpublished results).
6.2. The crystal structure of peroxisomal Type-II enzymes
The Type-II ACOTs (ACOT7 through ACOT13) all contain a similar
HotDog fold domain organization. While ACOT13 is predicted to

Fig. 3. X-ray crystallographic structure of human ACOT4. The overall structure of human
ACOT4 is a dimer (with one dimer labeled in yellow and the second dimer in green/orange)
with the monomer being composed of an N-terminal and a C-terminal domain. The Nterminal domain is composed of a seven-stranded β-barrel while the C-terminal domain
is a typical α/β hydrolase fold. The catalytic triad of serine–histidine–aspartic acid (S232,
H360, D326) present in the C-terminal domain is also indicated.
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contain a single HotDog domain, ACOT7 through ACOT12 contain two
tandem HotDog domains. To date, structural characterization of TypeII ACOTs by X-ray crystallography has revealed the structures of
mouse ACOT7 [67], human ACOT12 (PDB ID: 3B7K; Lehtiö et al.,
unpublished results) and the START domain of human ACOT11 [53].
So far, no structural data exists for any mammalian ACOT8. However,
while the Type-II enzymes show low similarity at the sequence level,
they show surprisingly high structural similarity. In this review we
therefore provide an overview on the current structural knowledge
of Type-II thioesterases and link this knowledge to understanding
the structural organization of human ACOT8.
Mouse ACOT7 and human ACOT12 show a sequence identity of
only 24.8%. Despite this low identity, the determination of their respective structures by X-ray crystallography revealed the same structural arrangement of the two HotDog domains. Each individual
HotDog fold features a central 5-stranded anti-parallel β-sheet
“bun” enveloping a ﬁve-turn α-helix “sausage”, two of which are
side by side resulting in a 10 stranded β-sheet core enclosing 2 αhelices. This architecture referred to as the double HotDog fold, then
associates into a trimeric quaternary structure (Fig. 4A). Both these
structures also contain an additional C-terminal external helix,
which packs on the opposite side of the central β-sheet.
The active site architecture appears similar in both mouse ACOT7 and
human ACOT12. Although both these enzymes contain tandem HotDog
domains of limited sequence similarity, they contain two structurally
analogous active sites per protein monomer. Based on mouse ACOT7
studies, only one of the two analogous sites is active, resulting in a single
active site per set of fused HotDog domains, suggesting that the second
site has more of a regulatory function [67]. Preliminary analysis of the
human ACOT12 structure also supports this half-site reactivity hypothesis
since only one coenzyme A molecule is present at the junction of the tandem HotDog domains of a human ACOT12 monomer.
Although detailed structural information is available for these
Type-II enzymes, only preliminary analysis of catalytic residues has
been performed. Although Asn24 and Asp213 have been identiﬁed
as required for activity in mouse ACOT7, the precise catalytic mechanisms of both mouse ACOT7 and human ACOT12 remain elusive.
However, a recent X-ray crystallographic study of Bacillus halodurans
ACOT (BhACOT) reveals signiﬁcant ligand-induced conformational
changes ([68]; PDB ID: 1VPM, 3SPS). Examination of the structure of
BhACOT, with respect to mouse ACOT7 and human ACOT12, reveals
a similar hexameric organization. Furthermore, the human ACOT12
bound to coenzyme A reveals the formation of a β-bulge at the junction of both HotDog domains, similar to that observed in BhACOT
upon ligand binding. This may suggest a common mechanism of action for the hexameric Type-II enzymes.
The structurally determined E. coli thioesterase II (TEII) shares
39.9% identity with human ACOT8, the highest percentage of identity

for any structurally determined Type-II enzyme ([69]; PDB ID: 1C8U).
Notably, the overall double HotDog fold described in the structures of
mouse ACOT7 and human ACOT12 is conserved in TEII. The X-ray
crystallographic structure of TEII revealed a similar 10-stranded βsheet core enclosing 2 α-helices, with an active site formed at the interface of both HotDog repeats (Fig. 4B). The overall structure shows
two major differences with the mammalian enzymes described
above. Firstly, its overall quaternary structure appears to be dimeric
forming a tetramer of HotDog domains as opposed to the hexamer
observed in both mouse ACOT7 and human ACOT12. Secondly,
while the main core of the protein monomer remains the same, the
placement of additional α-helices differs signiﬁcantly, which results
in differential active site placement (Fig. 4B).
In view of the above, some preliminary conclusions based on the
crystallographic structures of mouse ACOT7, human ACOT12 and TEII
toward the overall architecture of human ACOT8 can be made. Analysis
of secondary structure predictions for human ACOT8 using the PSIPRED
server [70], indicates a near identical β-sheet and α-helix topology as
per TEII. Furthermore, 3D structure predictions performed with
MODELLER [71] and 3D-JIGSAW (http://bmm.cancerresearchuk.org/
~3djigsaw/), predict a similar organization of human ACOT8 to TEII
with the main double HotDog fold being present with minor differences
in placement of additional α-helices surrounding the main double HotDog domain. Whether human ACOT8 will form a hexameric or a tetrameric organization of HotDog folds remains difﬁcult to predict.
However, the presence of a conserved catalytic triad between TEII
(Asp204-Gln278-Thr228) and human ACOT8 (Asp232-Gln306-Ser256),
in addition to a near 40% sequence identity suggests that human ACOT8
adopts a tetrameric dimer of the HotDog domain dimer organization as
does TEII. A dimeric organization of ACOT8 is further supported by the absence of any higher molecular mass thioesterase activity upon sizeexclusion chromatography of matrix proteins from rat liver peroxisomes
[72]. Although clear-cut conclusions concerning the precise mode of action of human ACOT8 cannot be drawn from 3D structure predictions,
the structural information may explain the CoASH-sensitivity of ACOT8.
The binding of CoASH in the structure of ACOT12 suggests that acylCoAs bind via the CoASH moiety and that CoASH may compete for this
binding and this may be a common feature of Type-II ACOTs.
7. Acyltransferases in peroxisomes involved in bile acid and fatty
acid amidation (conjugation)
7.1. The bile acid-CoA:amino acid N-acyltransferase conjugates bile acids
in peroxisomes
Bile acids are synthesized in liver and are involved in the intestinal
absorption of fats and fat-soluble vitamins and are also a means of excess cholesterol elimination from the body. Bile acids are produced

Fig. 4. Structural representation of Type-II thioesterases. (A) Human ACOT12 (PDB ID: 3B7K) is represented as a Type-II thioesterase that hexamerizes forming a trimer of tandem
HotDog folds. (B) Escherichia coli TEII (PDB ID: 1C8U) is represented as a Type-II thioesterase that tetramerizes forming a dimer of tandem HotDog folds. Ligands used in cocrystallization (coenzyme A in (A) and lauryl dimethylamine-N-oxide in (B)) and observed in X-ray crystallographic structures are marked, indicating active site positions.
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from cholesterol by a series of enzymatic steps involving multiple cellular
compartments, with the ﬁnal steps being the β-oxidation of the sidechain of the C27 bile acid precursors trihydroxycoprostanoyl-CoA and
dihydroxycoprostanoyl-CoA to choloyl-CoA and chenodeoxycholoylCoA (C24 bile acids) and a ﬁnal conjugation (or amidation) of the C24
primary bile acids to glycine or taurine (for review see [73,74]). This
ﬁnal conjugation step is carried out by BAAT in peroxisomes (Fig. 7).
The intracellular localization of BAAT has been widely discussed and
early studies in 1967 identiﬁed bile acid conjugation activity in the lysosomal fraction (or possibly the peroxisomal fraction) of human liver [75].
Later studies by Kase et al. identiﬁed BAAT activity in microsomal and
peroxisomal fractions in rat liver [76], with other groups identifying activity in microsomes, cytosol or peroxisomes in rat, mouse and human
[77–82]. In view of the apparent disparate data on expression of BAAT,
it was hypothesized that two pathways for bile acid conjugation exist,
one in peroxisomes which conjugates the CoA esters of the de novo synthesized primary bile acids (choloyl-CoA and chenodeoxycholoyl-CoA),
and a second pathway in cytosol involved in the re-conjugation of secondary bile acids (deoxycholic acid, and lithocholic acid) recycled back
to the liver via the enterohepatic circulation [77]. Human very long
chain acyl-CoA synthetase homolog 2 (VLCS- and also known as BACS,
bile acid-CoA synthetase) activates primary bile acids such as cholic
acid [83] and secondary bile acids (deoxycholic acid and lithocholic
acid) to their CoA esters [84] in the cytosol or endoplasmic reticulum,
also supporting two pathways of bile acid conjugation. Rembacz et al. recently showed that cholic acid (a primary bile acid) shuttles through peroxisomes in hepatocytes for taurine (and possibly glycine) conjugation
[85]. Since taurocholic acid was detected in isolated peroxisomes and
readily accumulated in hepatocytes, apparently transport of conjugated
bile acids across the peroxisomal membrane (via a as yet unambiguously
identiﬁed bile salt transporter, [86]), as well as across the plasma membrane via the bile salt export pump (BSEP), is rate-limiting in this process.
It would be of interest to determine if secondary bile acids shuttle
through peroxisomes for conjugation by BAAT and the debate as to
whether BAAT is also localized in cytosol to conjugate recycled secondary
bile acids remains open.
The rodent and human BAAT proteins all contain the variant peroxisome type-1 targeting signals of -SQL and the functionality of this PTS1variant has been a matter of debate. A peptide ending in -SQL ﬂanked
by a serine in the −4 position (-SSQL) was found to interact very weakly
with human Pex5p [87], while a peptide containing a basic amino acid
residue in the −4 position (-KSQL) interacted strongly with Pex5p,
which also targeted green ﬂuorescent protein (GFP) to peroxisomes in
HeLa cells [87]. In accordance with these ﬁndings, transfection of HeLa
cells with human and mouse wild-type BAAT-GFP fusion proteins
resulted in a cytosolic localization of the fusion proteins, while mutation
to a basic residue in the −1 position (-KSQL) targeted BAAT to peroxisomes [46]. Recent studies using GFP expression of BAAT and advanced
microscopy techniques have identiﬁed that BAAT is cytosolic in some
cell lines and is peroxisomal in other cell lines. In human and rat primary
hepatocytes, BAAT is localized in peroxisomes [88], whereas expression
studies in human ﬁbroblasts resulted in a cytosolic localization of BAAT
[88,89]. Competition studies in rat primary hepatocytes were carried
out using the human BAAT-GFP fusion protein and a peroxisomal marker
DSRed-SKL, which resulted in a cytosolic localization of BAAT, indicating
that the -SQL non-consensus targeting signal (e.g. in BAAT) is not as efﬁcient as the -SKL and that competition between these will occur, resulting
in a mislocalization of the non-consensus containing protein. These results suggest that the -SQL non-consensus targeting signal may have different efﬁciencies in different cell lines or may need interaction with some
other protein(s) in addition to Pex5p. It thus appears that the targeting of
BAAT to peroxisomes may be more complicated than previously thought
and that targeting may depend on the saturation of the import machinery
and competition between ‘consensus’ and ‘non-consensus’ PTS1s.
There are a number of studies identifying regulation of BAAT at
mRNA or protein level in mouse or rat but data on regulation of
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gene expression in human is more limited. In 1996, BAAT (then
known as kan-1) mRNA was measured by Northern blot in liver samples of resected patients suffering from hepatocellular carcinoma
(HCC) and it was suggested that BAAT could be used as a prognostic
marker in HCC patients following resection [90]. Human BAAT has recently been identiﬁed as being strongly associated with microRNA
miR492 expression in hepatoblastoma (HB), the most common childhood malignant liver tumor [91]. Three novel single nucleotide polymorphisms (SNPs) in the BAAT gene have been identiﬁed in the
Japanese population, two of which are silent mutations and one of
which results in the nonsynonymous Arg201Pro mutation [92]. However the functional implications of this latter mutation on BAAT activity have not been determined and Arg201 is not conserved in the
related ACOT and ACNAT proteins. Shonsey et al. recently identiﬁed
that the histidine residue localized in the AGH motif at position 362
in BAAT which is part of the catalytic triad of the protein (this His is
also conserved in all ACOT and ACNAT enzymes [89,93]), is modiﬁed
and forms adducts with 4-hydroxynonenal (4-HNE) at physiological concentrations [94]. 4-HNE is an electrophilic lipid generated by the oxidation
of polyunsaturated long-chain fatty acids, linking BAAT to models of
oxidative stress. The formation of these 4-HNE adducts with His 362
resulted in a dose-dependent reduction of BAAT activity, with activity reduced by 70% in the presence of 16 μM 4-HNE [94]. O'Byrne et al. also
identiﬁed that mutation of His 362 to Gln all but abolished human BAAT
activity [89].
7.2. The role of peroxisomes in the production of amidated fatty acids
In recent years, several amides of fatty acids that are structurally related to endocannabinoids (for review see [95]), have been
isolated from mammalian sources. One group of these fatty acid
amides are the N-acyl amino acids, which have generated renewed
research interest in part due to their structural relationship to
the endocannabinoids [96,97]. N-Acyl amino acids are fatty acids
conjugated (or amidated) to amino acids such as glycine, taurine,
alanine, serine etc. and fatty acid conjugates with the common
20 amino acids have now been identiﬁed in mammalian tissues
[96]. N-Acyl amino acids are emerging as putative signaling molecules with a wide range of biological activities (for review see
[98]).
Peroxisomes contain enzymatic pathways that produce taurine
and glycine conjugated (amidated) fatty acids. Human BAAT can
conjugate long- and very-long chain acyl-CoAs (C12:0–C26:0) to glycine [89] and taurine (Fig. 5), resulting in the production of N-acyl
amino acids, although the fatty acid conjugation activity of BAAT
represents about 10% of the bile acid conjugating activity of this enzyme. In addition, two acyl-CoA:amino acid N-acyltransferases
(ACNAT1 and ACNAT2) have been identiﬁed in mouse peroxisomes
in 2007 [93]. These two gene products show 55% sequence identity
to BAAT and are 95% identical to each other at amino acid level.
ACNAT1 and 2 are both targeted to peroxisomes and contain the
consensus peroxisomal targeting signal -SKL ([18,93] and Fig. 6).
Recombinant ACNAT1 catalyzes the conjugation of long-chain and
very long-chain saturated acyl-CoA esters (C16–C24-CoAs) to taurine, resulting in the production of N-acyl taurines (NATs) [93]. Interestingly, this enzyme had no conjugation activity with the
amino acid glycine and very low conjugating activity toward bile
acid-CoAs, making it a speciﬁc fatty acid taurine conjugating enzyme.
The substrate speciﬁcity for ACNAT2 has not yet been identiﬁed, but
given the high sequence identity between ACNAT1 and ACNAT2
(95%), it is speculated that ACNAT2 may conjugate unsaturated fatty
acids to taurine.
Supporting the characterization of ACNAT1 in 2007 as a taurineconjugating enzyme producing NATs, these NATs were identiﬁed invivo in the mouse [99,100]. The identiﬁcation of ACNAT1 in peroxisomes,
together with the identiﬁcation of fatty acyl-CoA taurine conjugating
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Fig. 5. The bile acid-CoA:amino acid N-acyltransferase (BAAT) conjugates fatty acids
to taurine. Recombinant human BAAT was expressed in BL21(DE3)pLysS cells and
puriﬁed as described in [89]. BAAT (2–5 μg) was incubated with 40 μM of various saturated acyl-CoA esters as indicated, plus or minus 50 mM taurine. Reactions were
measured spectrophotometrically as described in [89]. Thioesterase activity is
shown in black bars and activity in the presence of taurine (thioesterase and taurine
conjugation activity) is shown in hatched bars. Data shown are means ± S.E.M.
(n = 2/3).

activity for BAAT (Fig. 5, showing the activity±taurine) suggested that
peroxisomes could be involved in the production of NATs. A comprehensive study of the levels of NATs in mouse tissues was recently carried out,
showing that NATs (chain lengths C16:0, C18:0, C18:2, C20:4, C22:0 and C22:6)
are present in plasma, brown adipose tissue, heart, white adipose
tissue, spleen, lung, testis, kidney and liver [101]. N-Arachidonoyl
taurine has been detected in liver and kidney under normal conditions, with levels of N-arachidonoyl taurine and other NATs increasing substantially in the fatty acid amide hydrolase (FAAH) knockout
mouse model [102]. The ACNAT1 identiﬁed in mouse peroxisomes
cannot conjugate arachidonoyl-CoA (or other unsaturated acylCoA esters) to taurine and is active only with saturated acyl-CoAs,
and it may be that ACNAT2 is involved in the taurine conjugation
of unsaturated acyl-CoAs (Fig. 7). Long et al. have suggested the existence of a transport system for NATs that transfers these lipids
from liver to other tissues e.g. spleen [101]. Therefore NATs produced at one particular site could potentially be transported by
the plasma to other organs and may be transported out of peroxisomes via the yet unidentiﬁed bile acid transporter protein, which
can transport both glyco- and tauro-conjugated bile acids across
the peroxisomal membrane [86]. The physiological functions and
effects of increased levels of NATs are not well studied to date. NArachidonoyl taurine activates the transient receptor potential
vanilloid (TRPV) receptor 1 and 4 ion channels [102]. Very recently,

NATs (particularly N-oleoyl taurine and N-arachidonoyl taurine)
have been shown to have anti-proliferative effects in prostate
carcinoma PC-3 cells [103] and treatment of pancreatic β-cells
with NATs results in insulin release (Waluk et al., manuscript in
preparation).
The role of peroxisomes and BAAT in the production of glycine conjugated bile acids is well established (as described in Section 7.1). However, BAAT also has low glycine conjugating activity toward fatty acids
[89]. Several N-acyl glycines have been identiﬁed in vivo including Narachidonoyl glycine (NAGly — arachidonic acid conjugated to glycine),
N-oleoyl glycine, and N-palmitoyl glycine [104–107]. NAGly was identiﬁed in rat brain, spinal cord, small intestine and glabrous skin, with
low levels detected in liver [106]. NAGly is synthesized by several pathways, including an enzymatic conjugation of arachidonoyl-CoA with
glycine by BAAT [89], enzymatic conjugation of arachinonoyl-CoA
with glycine by glycine N-acyltransferase like-2 (GLYATL2) localized
in the endoplasmic reticulum [108], synthesis by cytochrome c in the
presence of arachidonoyl-CoA and hydrogen peroxide [109], and ﬁnally
by oxidation of anandamide (an endocannabinoid) by alcohol and aldehyde dehydrogenases [110]. A recent review on the identiﬁcation
and functions of N-acyl glycines [104] reveals that these lipid molecules
act as ligands for a number of G-protein coupled receptors such as
GPR18 [111], GPR92 [112] and GPR72 [113].
It is worthwhile noting that the connection between peroxisomes
and the production of signaling lipids such as N-acyl glycines and
NATs has not yet been studied in detail and it would be of interest to examine the levels of N-acyl glycines and NATs in patients with Zellweger
syndrome or other peroxisomal disorders, to ﬁrmly establish the role of
peroxisomes in the production of these ‘endocannabinoid-like’ lipids.
8. Human diseases associated with peroxisomal ACOTs and BAAT
To date, there is very limited information on the role of ACOTs in
human health. An isoform of ACOT7 (initially characterized as brain cytosolic acyl-CoA hydrolase, BACH, but with mitochondrial and cytosolic isoforms) was found to be deranged in the hippocampus of patients with
mesial temporal lobe epilepsy [114] and the mitochondrial isoform of
ACOT7 was decreased in mitochondria from patients with mitochondrial
fatty acid oxidation defects [115]. A recent mapping of genes associated
with human mitochondrial disorders identiﬁed ACOT9 (a mitochondrial
ACOT) associated with MEHMO syndrome (Mental retardation, Epileptic
seizures, Hypogenitalism, Microcephaly and Obesity) [116], an X-linked
disorder which includes symptoms such as mental retardation, seizures,
obesity, hypogonadism. However, so far, no speciﬁc peroxisomal disorders or single enzyme deﬁciencies have been identiﬁed in human for
ACOT proteins.
In human, many bile acid abnormalities exist in patients with peroxisomal disorders and these are covered in detail in a recent review

Fig. 6. Mouse ACNAT2 is localized in peroxisomes. The open reading frame of mouse Acnat2 was cloned in frame with green ﬂuorescent protein (GFP) and expressed in human skin
ﬁbroblasts. A GFP fusion protein containing -SKL (the consensus peroxisomal type 1 targeting signal) was also expressed in human skin ﬁbroblasts to label peroxisomes. Immunoﬂuorescence microscopy was carried out using a Tritc-labeled anti-GFP antibody. (A) Mouse ACNAT2 and (B) -SKL-GFP.
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Fig. 7. The role of acyltransferases in the production of N-acyl glycines and N-acyl taurines in peroxisomes. The precursors to primary bile acids, trihydroxycoprostanoyl-CoA (THCACoA) and dihydroxycoprostanoyl-CoA (DHCA-CoA) are transported into peroxisomes, possibly via ABCD3. Once inside the peroxisome, they undergo one cycle of β-oxidation to
produce chenodeoxycholoyl-CoA (CDCA-CoA) or choloyl-CoA (CA-CoA) (the CoA esters of the primary bile acids). BAAT then conjugates CDCA-CoA or CA-CoA to glycine or taurine,
resulting in the production of glycocholate, taurocholate, glycochenodeoxycholate or taurochenodeoxycholate. These primary bile acids are then exported from the peroxisome (by
a yet unidentiﬁed transporter) to bile. Primary bile acids can also act as ligands for the farnesoid X receptor (FXR). Saturated and unsaturated very long-chain fatty acids (VLCFACoA) are imported into peroxisomes as CoA esters via the ABCD1 and ABCD2 transporters. These fatty acids then undergo chain shortening via the peroxisomal β-oxidation system,
producing long or medium-chain acyl-CoAs. Very long-chain, long-chain or medium-chain acyl-CoAs can then be conjugated to glycine (by BAAT) or to taurine (by ACNAT1 or
BAAT) (for simplicity, only the conjugation of long-chain acyl-CoAs (LCFA-CoA) is shown in the ﬁgure). Taurine conjugated fatty acids can function as cell signaling molecules
for e.g. the Transient Receptor Potential Vanilloid (TRPV) receptors TRPV1 and TRPV4. Glycine conjugates function in activation of G-protein coupled receptors (GPRs).

[74]. However, to date only one human disease has been identiﬁed
where BAAT is directly implicated. BAAT is involved in the inheritance
of familial hypercholanemia [117]. Familial hypercholanemia is characterized by increased levels of serum bile acids, itching and fat malabsorption. A study on members of the Amish population identiﬁed a
mutation in BAAT, 226A-G mutation, resulting in a M76V mutation,
which is a highly conserved methionine in all ACOT, ACNAT and
BAAT proteins. Individuals with the BAAT M76V mutation had associated lower levels of conjugated bile acids and serum analysis revealed
that bile acids were mainly unconjugated [117]. BAAT is a member of
the α/β hydrolase protein family and contains an active site with a
variant of the α/β hydrolase GlyXaaSerXaa lipase motif (GxSxG
motif). In human, rat and mouse BAAT the motif contains a cysteine
as the nucleophilic residue in a SerXaaCysXaaGly (SxCxG) motif, together with a histidine and aspartic acid, which form the catalytic
triad [89,118]. Mutation of the active site cysteine (SxCxG) to alanine
(SxAxG) abolishes BAAT activity [89], however it is not known what
effect the M76V mutation will have on the activity of BAAT. This mutation would be located in the ﬁrst exon of the BAAT/ACOT/ACNAT
proteins, which contributes the N-terminal domain, whereas all
amino acids in the active site are located in the third exon [13,17].
As discussed above (in Section 6.1) the function of the N-terminal domain is not yet understood, but since this domain contributes to the
active site it is conceivable that mutation of the highly conserved
Met76 may distort the structure of this domain and thereby affect
the active site of BAAT. It would be of interest to create the same mutation to assess the effect on structure and activity of ACOTs and
BAAT.
9. Future perspectives
Although our knowledge of ACOT and acyltransferase enzymes in
peroxisomes has expanded greatly in the past number of years, there
is still a large body of work to be completed in respect of the

physiological effects of the lack of ACOT or acyltransferase enzymes
in-vivo, in human or animal models, and their interactions with
other cellular proteins. Further structural characterization of both
Type-I and Type-II ACOTs would help our understanding of their
functions with regard to substrate speciﬁcity and allosteric regulation. Overexpression, silencing and gene knockouts should provide
more insight into the functions of ACOTs in health and disease.
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